Personalized medicine will change the way medicine is practiced. The new therapies will benefit both patients and physicians in many ways. Patients will experience fewer side effects and physicians will be armed with more precise tools and medicine. Companion diagnostic co-development has the potential to significantly alter the drug development process and commercialization of drug candidates by yielding safer drugs with enhanced therapeutic efficacy in a faster, more cost-effective manner. This premier B2B summit will bring together experts from all levels of the value chain to analyze and tackle the latest and greatest opportunities in the CDx.
The summit ensures maximum knowledge transfer among professionals and decision makers to exchange and elaborate on the best practices within the companion diagnostics (CDx) industry. More importantly, partnership opportunities and commercializing CDx tests with pharmaceutical and biotech companies will be explored.
7 Mar 2019 @ 08:00 am
8 Mar 2019 @ 04:00 pm
Duration: 1 days, 8 hours